Literature DB >> 7831485

The common mucosal immune system: from basic principles to enteric vaccines with relevance for the female reproductive tract.

J R McGhee1, J Xu-Amano, C J Miller, R J Jackson, K Fujihashi, H F Staats, H Kiyono.   

Abstract

The realization that induction of immune responses at mucosal surfaces may prevent colonization, invasion or dissemination of pathogenic microorganisms has spurred intensive efforts to develop vaccines which elicit effective mucosal immunity. In this paper, recent results are discussed for mice given cholera toxin as both an immunogen and as an adjuvant for inducing both humoral and gastrointestinal mucosal immune responses. Oral administration of cholera toxin alone or with a co-administered protein vaccine tetanus toxoid induces a strong T helper type 2 (TH2) cell response in both Peyer's patches and spleen. Both serum IgG and secretory IgA antibodies specific for cholera toxin or for the co-administered protein tetanus toxoid were induced. When administered parentally, however, no mucosal antibody responses were evident and a mixed TH1- and TH2-type CD4+ T cell response was noted in the spleen. Various vectors are being employed in an effort not only to induce mucosal immune responses but also to direct the response to a TH1-type response, thought to promote strong cell-mediated immune responses, or to a TH2-type response for maximum B cell antibody responses. The ability to manipulate the TH cell responses may provide a more rational approach for the design of vaccines. Although lymphoid tissues of the female reproductive tract differ from that of the gut, many of the strategies and evolving principles may be directly applicable to the development of vaccines designed to prevent sexually transmitted diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7831485     DOI: 10.1071/rd9940369

Source DB:  PubMed          Journal:  Reprod Fertil Dev        ISSN: 1031-3613            Impact factor:   2.311


  8 in total

1.  Distribution of lymphocytes and adhesion molecules in human cervix and vagina.

Authors:  E L Johansson; A Rudin; L Wassén; J Holmgren
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

2.  Further characterization of immunomodulation by a monoclonal antibody against Streptococcus mutans antigen P1.

Authors:  Nikki R Rhodin; Marloes L J A Van Tilburg; Monika W Oli; William P McArthur; L Jeannine Brady
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 3.  Use of nonhuman primate models to develop mucosal AIDS vaccines.

Authors:  Meritxell Genescà; Christopher J Miller
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

4.  Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product.

Authors:  Zhiquan Xiang; Guangping Gao; Arturo Reyes-Sandoval; Christopher J Cohen; Yan Li; Jeffrey M Bergelson; James M Wilson; Hildegund C J Ertl
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Oral antigen exposure in newborn piglets circumvents induction of oral tolerance in response to intraperitoneal vaccination in later life.

Authors:  J Alex Pasternak; Siew Hon Ng; Rachelle M Buchanan; Sonja Mertins; George K Mutwiri; Volker Gerdts; Heather L Wilson
Journal:  BMC Vet Res       Date:  2015-03-07       Impact factor: 2.741

6.  Low dose antigen exposure for a finite period in newborn rats prevents induction of mucosal tolerance.

Authors:  Rachelle M Buchanan; Sherry Tetland; Heather L Wilson
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

7.  Oral antigen exposure in extreme early life in lambs influences the magnitude of the immune response which can be generated in later life.

Authors:  Rachelle M Buchanan; Sonja Mertins; Heather L Wilson
Journal:  BMC Vet Res       Date:  2013-08-12       Impact factor: 2.741

Review 8.  Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases.

Authors:  Fengling Feng; Ziyu Wen; Jiaoshan Chen; Yue Yuan; Congcong Wang; Caijun Sun
Journal:  Viruses       Date:  2022-03-03       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.